Leukemia

CRISPR-created human GATA2 deficiency causes cell division problems and early aging in blood stem cells, reducing their health

Updated

Abstract

Human CD34⁺ cells with the GATA2-R398W mutation show a significant fitness disadvantage in vivo compared to wild-type cells.

  • GATA2 deficiency is linked to bone marrow failure, immunodeficiency, and increased risk of myelodysplastic neoplasms and acute myeloid leukemia.
  • The GATA2-R398W mutation impairs cell proliferation and disrupts the normal cell cycle.
  • GATA2 mutations, even in combination with mutations in SETBP1 and ASXL1, lead to reduced fitness in hematopoietic stem cells.
  • Transcriptomic analysis indicates that GATA2-mutant cells exhibit reduced self-renewal capacity and signs of pre-aging.
  • A novel humanized model was developed using CRISPR/Cas9 to study the effects of GATA2 variants.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Competing interests: The authors declare no conflicts of interest. Ethics approval and consent to participate: All methods described in this manuscript were performed in accordance with the relevant guidelines and regulations. The animal experiments in this study have been approved by our Animal Ethics Committee of PRBB and are conducted in accordance with the regulation from the “Departament de Medi Ambient i Habitatge de la Generalitat de Catalunya” with the protocol number 10655; Ethics Committee on Animal Experimentation (CEEA): ABS-19-0045-P4. Healthy donors mobilized peripheral blood CD34+ cells were obtained with written informed consent and approval of the Institutional Review Board (IRB) of Fred Hutchinson Cancer Research Center with the approval number #985.03. Cord blood units from healthy newborns were obtained from the Blood Tissue Bank following the institutional guidelines approved by the local IRB with the approval number 206-173-1. All patients or their guardians signed informed consents for sample collection in accordance with the Declaration of Helsinki.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free